NRGN and Alzheimer disease: Compared to these, our study is novel by simultaneously investigating CSF T‐tau, Ng, and NFL and by testing whether these biomarkers provide independent information about AD diagnosis and brain changes associated with AD in several different clinical stages of the disease.